Ajay K. Singh, MBBS, FRCP, MBA
Articles by Ajay K. Singh, MBBS, FRCP, MBA
Ajay Singh pays tribute to the late nephrologist and researcher Nicolaos Madias, MD, of Tufts Medical Center.
The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW.
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
Ajay K. Singh discussed his findings on daprodustat dosing and utilization of finerenone.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
The first part of the dialysis moonshot is to prevent the need for dialysis.
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
The most important patients who should receive treatment with SGLT2 inhibitors are those with CKD and type 2 diabetes.
Sodium-glucose transport protein 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, block SGLT2 cotransporters in the ...
Editor's Note:
...
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.